Successful Management of Osimertinib-Induced Heart Failure

Atsuko Fukuo, Teruhiko Imamura*, Hiroshi Onoda, Koichiro Kinugawa

*この論文の責任著者

研究成果: ジャーナルへの寄稿学術論文査読

5 被引用数 (Scopus)

抄録

Cancer therapeutics-related cardiac dysfunction is currently of great concern as one of the pivotal therapeutic targets of onco-cardiology. Only a few studies have reported the occurrence of heart failure following the administration of osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for EGFR mutation-positive advanced non-small cell lung cancer. We report on a 74-year-old woman with osimertinib-induced advanced heart failure with reduced ejection fraction, which was treated by the temporal termination of osimertinib and neurohormonal blocker therapy, as well as heart rate modulation therapy using ivabradine. Despite osimertinib-induced heart failure being relatively rare, aggressive neurohormonal blocker therapy using ivabradine if applicable, as well as the temporal termination of osimertinib, might be a promising therapeutic strategy.

本文言語英語
論文番号312
ジャーナルMedicina (Lithuania)
58
2
DOI
出版ステータス出版済み - 2022/02

ASJC Scopus 主題領域

  • 医学一般

フィンガープリント

「Successful Management of Osimertinib-Induced Heart Failure」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル